Coming Down the Pike: hES cells
The most significant early-stage discovery to hit the journals in late 2007 were the dual announcements from two independent research groups that they turned adult human skin cells into cells with properties that are seemingly identical with human embryonic stem (hES) cells.
The most significant early-stage discovery to hit the journals in late 2007 (or at least the most highly publicized) were the dual announcements from two independent research groups that they had managed to turn adult human skin cells into cells with properties that are seemingly identical with human embryonic stem (hES) cells. The teams each inserted four genes (only two of which overlap) into the adult cells to make them revert to the embryonic-like state. Among other things, the achievement may allow US scientists to explore the properties of hES cells—and their potential uses in regenerative medicine—while circumventing the debate on the morality of destroying human embryos to get the cells. Of course, both teams a nd scientific commentators stress that it will take a while to determine how similar the so-called induced pluripotent cells are to true hES cells. For now, however, it may allow US scientists to catch up to foreign counterparts studying hES cells.
Sources:
1. J. Yu, M. A. Vodyanik, K. Smuga-Otto, J. Antosiewicz-Bourget, J. L. Frane, S. Tian, J. Nie, G. A. Jonsdottir, V. Ruotti, R. Stewart, I. I. Slukvin, J. Thomson, "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells," SCIENCEXPRESS, www.sciencexpress.org/, accessed Nov. 20, 2007.
2. K. Takahashi, K. Tanabe, M. Ohnuki, M Narita, T. Ichisaka, K. Tomoda, and S. Yamanaka, "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors," Cell (2007), doi: 10.1016/j.cell.2007.11.019.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
